Credit Suisse’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-63,939
| Closed | -$217K | – | 3081 |
|
|
2023
Q3 | $217K | Sell |
63,939
-9,151
| -13% | -$50.7K | ﹤0.01% | 3013 |
|
|
2023
Q2 | $537K | Buy |
73,090
+35,585
| +95% | +$330K | ﹤0.01% | 2740 |
|
|
2023
Q1 | $389K | Sell |
37,505
-281
| -0.7% | -$3.4K | ﹤0.01% | 2882 |
|
|
2022
Q4 | $446K | Sell |
37,786
-1,450
| -4% | -$22.4K | ﹤0.01% | 2856 |
|
|
2022
Q3 | $824K | Sell |
39,236
-5,572
| -12% | -$155K | ﹤0.01% | 2461 |
|
|
2022
Q2 | $1.39M | Sell |
44,808
-5,131
| -10% | -$175K | ﹤0.01% | 2158 |
|
|
2022
Q1 | $2.05M | Buy |
49,939
+1,153
| +2% | +$50.9K | ﹤0.01% | 2058 |
|
|
2021
Q4 | $2.12M | Sell |
48,786
-288
| -0.6% | -$13K | ﹤0.01% | 2740 |
|
|
2021
Q3 | $2.46M | Buy |
49,074
+5,571
| +13% | +$337K | ﹤0.01% | 2666 |
|
|
2021
Q2 | $2.78M | Sell |
43,503
-2,360
| -5% | -$152K | ﹤0.01% | 2584 |
|
|
2021
Q1 | $4.26M | Sell |
45,863
-31,405
| -41% | -$3.22M | ﹤0.01% | 2204 |
|
|
2020
Q4 | $6.92M | Buy |
77,268
+20,323
| +36% | +$1.87M | ﹤0.01% | 1839 |
|
|
2020
Q3 | $5.88M | Sell |
56,945
-14,527
| -20% | -$1.57M | ﹤0.01% | 1686 |
|
|
2020
Q2 | $5.65M | Buy |
71,472
+14,184
| +25% | +$1.06M | ﹤0.01% | 1629 |
|
|
2020
Q1 | $3.31M | Sell |
57,288
-9,379
| -14% | -$540K | ﹤0.01% | 1779 |
|
|
2019
Q4 | $3.6M | Buy |
66,667
+34,029
| +104% | +$1.85M | ﹤0.01% | 2135 |
|
|
2019
Q3 | $1.71M | Buy |
32,638
+3,304
| +11% | +$154K | ﹤0.01% | 2597 |
|
|
2019
Q2 | $1.42M | Sell |
29,334
-22,129
| -43% | -$1.06M | ﹤0.01% | 2688 |
|
|
2019
Q1 | $2.6M | Sell |
51,463
-24,235
| -32% | -$1.43M | ﹤0.01% | 2181 |
|
|
2018
Q4 | $4.49M | Buy |
75,698
+41,545
| +122% | +$2.68M | ﹤0.01% | 1649 |
|
|
2018
Q3 | $2.25M | Sell |
34,153
-12,825
| -27% | -$748K | ﹤0.01% | 2273 |
|
|
2018
Q2 | $2.37M | Buy |
46,978
+12,715
| +37% | +$662K | ﹤0.01% | 2311 |
|
|
2018
Q1 | $1.8M | Buy |
34,263
+4,099
| +14% | +$204K | ﹤0.01% | 2512 |
|
|
2017
Q4 | $1.4M | Sell |
30,164
-13,517
| -31% | -$569K | ﹤0.01% | 2737 |
|
|
2017
Q3 | $1.77M | Buy |
43,681
+13,788
| +46% | +$499K | ﹤0.01% | 2653 |
|
|
2017
Q2 | $1.01M | Sell |
29,893
-37,905
| -56% | -$1.17M | ﹤0.01% | 2690 |
|
|
2017
Q1 | $1.97M | Buy |
67,798
+18,078
| +36% | +$550K | ﹤0.01% | 2365 |
|
|
2016
Q4 | $1.63M | Sell |
49,720
-803
| -2% | -$24.1K | ﹤0.01% | 2600 |
|
|
2016
Q3 | $1.59M | Sell |
50,523
-961
| -2% | -$27.9K | ﹤0.01% | 2552 |
|
|
2016
Q2 | $1.45M | Buy |
51,484
+24,860
| +93% | +$975K | ﹤0.01% | 2606 |
|
|
2016
Q1 | $969K | Buy |
26,624
+14,106
| +113% | +$498K | ﹤0.01% | 2749 |
|
|
2015
Q4 | $501K | Sell |
12,518
-7,115
| -36% | -$248K | ﹤0.01% | 3378 |
|
|
2015
Q3 | $560K | Sell |
19,633
-22,843
| -54% | -$753K | ﹤0.01% | 3313 |
|
|
2015
Q2 | $1.4M | Buy |
42,476
+8,260
| +24% | +$256K | ﹤0.01% | 2864 |
|
|
2015
Q1 | $984K | Sell |
34,216
-1,456
| -4% | -$41.8K | ﹤0.01% | 2987 |
|
|
2014
Q4 | $971K | Sell |
35,672
-25,233
| -41% | -$601K | ﹤0.01% | 3151 |
|
|
2014
Q3 | $1.3M | Sell |
60,905
-23,636
| -28% | -$541K | ﹤0.01% | 2831 |
|
|
2014
Q2 | $1.9M | Sell |
84,541
-19,568
| -19% | -$456K | ﹤0.01% | 2765 |
|
|
2014
Q1 | $2.63M | Buy |
104,109
+8,063
| +8% | +$204K | ﹤0.01% | 2306 |
|
|
2013
Q4 | $2.21M | Buy |
96,046
+53,207
| +124% | +$1.11M | ﹤0.01% | 2565 |
|
|
2013
Q3 | $816K | Buy |
+42,839
| New | +$765K | ﹤0.01% | 3123 |
|
Other funds holding EBS
Credit Suisse's EBS Position: Q4 2023 in Review
Credit Suisse sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 63,939 shares — an estimated $217K sold.
Credit Suisse first reported a position in EBS in Q3 2013 and held it in 41 quarters. The position peaked at $6.92M in Q4 2020. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.
- Credit Suisse reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 63,939 Emergent Biosolutions shares in Q4 2023, an estimated $217K.
- Credit Suisse first reported a position in Emergent Biosolutions in Q3 2013 and held it in 41 quarters.
- Credit Suisse's Emergent Biosolutions position peaked at $6.92M in Q4 2020.
- 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.